Studies addressing the neuroprotective efficacy of VIP in a Parkinson's disease model revealed that VIP could prevent MPTP-induced nigrostriatal dopaminergic neuronal death by blocking microglial activation [36]. Here, VIP is linked to Parkinson disease.